Therefore, a better understanding of the biology of CML-BC is necessary to identify molecular networks that, if appropriately modulated, will simultaneously affect the function of BCR/ABL and that of multiple signals aberrantly activated in CML-BC. The gene discussed is ABL1; the disease is breast cancer.